Additionally, a study on durvalumab (PD-L1 blocker) combined with albumin paclitaxel and doxorubicin/cyclophosphamide in the treatment of triple-negative breast cancer also demonstrated that the expression of CCL3, CCL5, and other chemokines increased post-chemotherapy, and these chemokines promoted the recruitment of macrophages to the tumor site [26]. This evidence concerns the gene CCL3 and triple-negative breast carcinoma.